1-4 of 4
Ulrike Klein
Close
Sort by
Journal Articles

Single Center Experience of Lenalidomide/Dexamethasone Treatment in 40 Patients with Light Chain Amyloidosis: High Toxicity in Patients with Severe Impaired Renal and Cardiac Function.

Stefan O Schoenland, Tilmann Bochtler, Sascha Dietrich, Ulrike Klein, Hartmut Goldschmidt, Anthony Ho, Ute Hegenbart
Journal: Blood
Blood (2008) 112 (11): 1736.
https://doi.org/10.1182/blood.V112.11.1736.1736
Published: 2008
Journal Articles

High-Dose Therapy with Peripheral Blood Stem Cell Transplantation for Patients with Multiple Myeloma: Prognostic Impact of Chromosomal Aberrations and Correlation with the ISS-Score

Kai Neben, MD, Anna Jauch, Ph.D., Dirk Hose, MD, Friedrich Cremer, MD, Christiane Heiss, Thomas Hielscher, Uta Bertsch, MD, Ulrike Klein, MD, Jens Hillengass, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2008) 112 (11): 2708.
https://doi.org/10.1182/blood.V112.11.2708.2708
Published: 2008
Journal Articles

Efficacy and Tolerability of Lenalidomide/Dexamethasone in Intensively Pretreated Myeloma Patients: Experiences from the German Named Patient Program.

Ulrike Klein, MD, Igor W. Blau, MD, Monika Engelhardt, Jan P. Simon, MD, Hartmut Goldschmidt, Hermann Einsele, Stefan Knop, MD
Journal: Blood
Blood (2007) 110 (11): 4834.
https://doi.org/10.1182/blood.V110.11.4834.4834
Published: 2007
Journal Articles

CD56 as Prognostic Factor in Patients with Multiple Myeloma Treated by High-Dose Chemotherapy and Autologous Stem Cell Transplantation.

Michael Hundemer, MD, Ulrike Klein, MD, Dirk Hose, MD, Friedrich Cremer, MD, Marc Raab, MD, Marion Moos, PhD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2004) 104 (11): 947.
https://doi.org/10.1182/blood.V104.11.947.947
Published: 2004